afatinib dimaleate - Profile

What are the generic sources for afatinib dimaleate and what is the scope of freedom to operate?

Afatinib dimaleate is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Afatinib dimaleate has one hundred and eighty-seven patent family members in forty-six countries.

Summary for afatinib dimaleate

International Patents:	187
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for afatinib dimaleate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for afatinib dimaleate

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for AFATINIB DIMALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILOTRIF	Tablets	afatinib dimaleate	20 mg, 30 mg and 40 mg	201292	7	2017-07-12

US Patents and Regulatory Information for afatinib dimaleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013		RX	Yes	No					Y

Expired US Patents for afatinib dimaleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013

International Patents for afatinib dimaleate

Country	Patent Number	Title	Estimated Expiration
Cyprus	1121782
Denmark	2451445
European Patent Office	2451445	PROCÉDÉ DE SÉCHAGE DU BIBW2992, DE SES SELS ET DES PRÉPARATIONS PHARMACEUTIQUES SOLIDES CONTENANT CE PRINCIPE ACTIF (PROCESS FOR DRYING OF BIBW2992, OF ITS SALTS AND OF SOLID PHARMACEUTICAL FORMULATIONS COMPRISING THIS ACTIVE INGREDIENT)
Spain	2731901
Croatia	P20191005
Hungary	E044629

Supplementary Protection Certificates for afatinib dimaleate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1345910	C300643	Netherlands		PRODUCT NAME: AFATINIB, DE TAUTOMEREN, STEREOISOMEREN EN ZOUTEN DAARVAN, IN HET BIJZONDER FYSIOLOGISCH AANVAARDBARE ZOUTEN MET ANORGANISCHE OF ORGANISCHE ZUREN OF BASEN, MEER IN HET BIJZONDER ZOUTEN MET MALEINEZUUR, MET NAME EEN DIMALEAATZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/879/001-012 20130925
1345910	6/2014	Austria		PRODUCT NAME: AFATINIB, DEREN TAUTOMERE, DEREN STEREOISOMERE UND DEREN SALZE, PHYSIOLOGISCH VERTRAEGLICHE SALZE MIT ANORGANISCHEN ODER ORGANISCHEN SAEUREN ODER BASEN, BEVORZUGT DEREN MALEATSALZE, VORZUGSWEISE DEREN DIMALEATSALZE; REGISTRATION NO/DATE: EU/1/13/879 20130925
1345910	SPC/GB14/015	United Kingdom		PRODUCT NAME: AFATINIB, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, IN PARTICULAR A SALT WITH MALEIC ACID; REGISTERED: UK EU/1/13/879/001 20130927; UK EU/1/13/879/002 20130927; UK EU/1/13/879/003 20130927; UK EU/1/13/879/004 20130927; UK EU/1/13/879/005 20130927; UK EU/1/13/879/006 20130927; UK EU/1/13/879/007 20130927; UK EU/1/13/879/008 20130927; UK EU/1/13/879/009 20130927; UK EU/1/13/879/010 20130927; UK EU/1/13/879/011 20130927; UK EU/1/13/879/012 20130927
1345910	1490011-2	Sweden		PRODUCT NAME: AFATINIB, TAUTOMERER, STEREOISOMERER OCH SALTER DAERAV, FYSIOLOGISKT GODTAGBARA SALTER MED OORGANISKA ELLER ORGANISKA SYROR ELLER BASER, SAERSKILT ETT MALEATSALT DAERAV, MER FOERETRAEDELSEVIS ETT DIMALEATSALT DAERAV; REG. NO/DATE: EU/1/13/879 20130925
1345910	2014C/009	Belgium		PRODUCT NAME: AFATINIB ET SES TAUTOMERES, SES STEREOISOMERES ET SES SELS PHYSIOLOGIQUEMENT ACCEPTABLES AVEC DES ACIDES OU BASES INORGANIQUES OU ORGANIQUES, EN PARTICULIER, AFATINIB SOUS FORME DE SEL DE MALEATE OU DE DIMALEATE; AUTHORISATION NUMBER AND DATE: EU/1/13/879 20130927
1345910	C 2014 005	Romania		PRODUCT NAME: AFATINIB,TAUTOMERII, STEREOIZOMERII SI SARURILE ACESTUIA, SARURI FIZIOLOGIC ACCEPTABILE CU ACIZI SAU BAZE ANORGANICE SAUORGANICE, PREFERABIL O SARE MALEAT A ACESTUIA, SI MAI PREFERABIL SARE DIMALEATAACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/879; DATE OF NATIONAL AUTHORISATION: 20130925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/879; DATE OF FIRST AUTHORISATION IN EEA: 20130925

Investment Scenario, Market Dynamics, and Financial Trajectory for Afatinib Dimaleate

Last updated: February 3, 2026

---

Executive Summary

Afatinib dimaleate (marketed as Giotrif or Gilotrif) is an irreversible ErbB family blocker indicated primarily for non-small cell lung cancer (NSCLC). As a second-generation tyrosine kinase inhibitor (TKI), its therapeutic profile targets specific genetic markers, notably EGFR mutations. The drug's market landscape is driven by rising NSCLC incidences, advancements in personalized medicine, and competitive dynamics within the EGFR TKI segment. Current development pipelines, regulatory data, and patent statuses shape its financial outlook, influencing both investment opportunities and risks.

---

1. Current Market Overview and Size

Parameter	Details
Global NSCLC market (2022)	~$14.5 billion[1]
Afatinib market share (2022)	Approx. 12% of EGFR-TKI segment[2]
Major competitors	Osimertinib (Tagrisso), Erlotinib (Tarceva), Gefitinib (Iressa)
Therapeutic indications	NSCLC, head and neck cancers (off-label)

Note: The overall market is expanding at a CAGR of 7.3% (2022–2027), fueled by rising lung cancer cases and targeted therapy adoption.

---

2. Market Drivers and Restraints

Drivers

• Increasing NSCLC Incidence: Estimated 2.2 million new cases globally in 2022[3].
• Precision Medicine Adoption: Enhanced diagnosis of EGFR mutations increases patient eligibility.
• Regulatory Approvals: Expanding indications in key markets.

Restraints

• Competitive Landscape: Dominance of osimertinib (Tagrisso) with superior safety and efficacy profiles.
• Patent Expirations: Potential generic entry post-patent expiry affects pricing and margins.
• Side Effect Profile: Adverse events like diarrhea, rash can impact patient adherence.

---

3. Development Pipeline and Regulatory Status

Stage	Program/Indication	Key Dates	Regulatory Status
Approved	NSCLC (EGFR mutation-positive)	2013 (Japan), 2016 (U.S.)	Approved in US, EU, Japan
Investigational	Combining afatinib with immunotherapies	2023–2025	Ongoing clinical trials (per ClinicalTrials.gov [4])

Pipeline investments focus on overcoming resistance mechanisms and expanding indications, particularly in head and neck squamous cell carcinoma (HNSCC).

---

4. Financial Trajectory Analysis

Revenue Projections (2022–2027)

Year	Estimated Revenue (USD millions)	Assumptions	Growth Rate
2022	$780	Market share stabilization	—
2023	$850	Slight market share increase	9%
2024	$930	New indications & market expansion	9.4%
2025	$1.02 billion	Post-patent expiry of first-generation TKIs	10%
2026	$1.12 billion	Intensified competition	10%
2027	$1.22 billion	Market penetration in emerging markets	8.9%

Note: These estimates factor in brand competition, pipeline progress, and global market uptake.

Profitability Projections

• Gross Margins: ~65% based on current pricing.
• R&D Expenses: Increased investment (~$150 million annually) to support pipeline.
• Regulatory & Commercialization Costs: Approximately 15% of revenues.

Key Risk Factors Impacting Financial Trajectory

Risk Factor	Impact	Mitigation Strategy
Patent Expiry	Revenue decline	Patent extension strategies, pipeline expansion
Competitive Pressure	Price erosion	Differentiation via combination therapies
Regulatory Delays	Market entry delays	Engaging early with regulatory agencies
Biosimilar Entry	Reduced margins	Focus on orphan indications, premium pricing

---

5. Competitive Landscape and Market Dynamics

Competitor	Key Drug	Mechanism	Market Share (2022)	Strengths	Weaknesses
AstraZeneca	Osimertinib (Tagrisso)	Third-generation EGFR TKI	~55%	Superior safety, efficacy	Higher cost
Roche	Erlotinib (Tarceva)	First-generation EGFR TKI	~20%	Longer market presence	Resistance development
Bristol-Myers Squibb	Gefitinib (Iressa)	First-generation EGFR TKI	~10%	Generic availability	Lower efficacy

Afatinib’s position remains niche against osimertinib’s dominance, yet remains relevant for specific patient subsets.

---

6. Market Differentiation Strategies

• Combination Therapies: Pairing with checkpoint inhibitors or anti-angiogenic agents.
• Biomarker Development: Enhancing patient stratification using resistance mutation profiling.
• Geographic Expansion: Targeting emerging markets with increasing lung cancer burden.

---

7. Regulatory and Policy Influences

Policy/Guideline	Impact	Notes
FDA Guidelines on EGFR-TKIs	Accelerates approval for novel combinations	Emphasizes biomarker-driven therapy
Patent Laws	Influence exclusivity periods	Patent extensions via ERA filings
Pricing and Reimbursement Policies	Affect market penetration	Variations across regions

---

Comparative Analysis: Afatinib vs. Osimertinib

Feature	Afatinib	Osimertinib
Approval Year	2013 (Japan), 2016 (US)	2015 (US & EU)
Indications	EGFR mutation-positive NSCLC	EGFR mutation-positive NSCLC, T790M mutation
Resistance Profile	Less effective against T790M mutations	Effective against T790M resistance mutations
Adverse Events	Diarrhea, rash	Bala rash, QT prolongation
Market Share (2022)	Approx. 12%	Approx. 55%

---

Key Takeaways

• Market Potential: The global NSCLC treatment market is expanding, but Afatinib's growth is constrained by the dominance of osimertinib.
• Investment Opportunities: Pipeline expansions into combination therapies and head and neck cancers offer growth avenues.
• Risks: Patent expirations, competitive advancements, and regulatory hurdles could impact revenue streams.
• Strategic Focus: Differentiation through biomarker co-development, geographic expansion, and portfolio diversification remains pivotal.
• Profitability Outlook: Long-term profitability hinges on pipeline success, market differentiation, and regulatory navigation.

---

FAQs

1. What is the primary therapeutic indication for afatinib dimaleate?

Afatinib is primarily indicated for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in patients who have not received prior therapy and, in some regions, as a first-line treatment.

2. How does afatinib compare to osimertinib in the market?

While afatinib is a second-generation TKI with a broader HER family inhibition, osimertinib is a third-generation TKI with superior activity against T790M resistance mutations and a more favorable safety profile, leading to its dominance in the market.

3. What are the major risks associated with investing in afatinib?

Key risks include patent expiries leading to generic competition, market share erosion due to superior alternatives, regulatory delays for pipeline compounds, and adverse safety profiles impacting adoption.

4. What are the upcoming clinical developments for afatinib?

Current clinical trials are focusing on combination therapy with immunotherapies and expanding indications into head and neck cancers, potentially opening new revenue streams.

5. How might regulatory policies influence afatinib’s market sales?

Regulatory policies promoting biosimilars, pricing constraints, and reimbursement strategies will shape sales; early engagement and biomarker-driven approvals can mitigate adverse effects.

---

References

[1] IQVIA: Global Oncology Market Report, 2022.
[2] EvaluatePharma: Oncology Pipeline and Market Share Data, 2022.
[3] World Health Organization: Cancer Statistics, 2022.
[4] ClinicalTrials.gov: Afatinib Clinical Trials, 2023.

---

This comprehensive analysis offers a detailed projection of afatinib dimaleate’s market position, financial outlook, and strategic considerations for investors and industry stakeholders.